Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting

Journal of the National Cancer Institute

Volumn 101, Issue 23, 2009, Pages 1612-1623

  Leinonen, Maarit ^a   Nieminen, Pekka ^b   Kotaniemi Talonen, Laura ^a   Malila, Nea ^a,c   Tarkkanen, Jussi ^b   Laurila, Pekka ^b   Anttila, Ahti ^a  

^a FINNISH CANCER REGISTRY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; ASSAY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DNA SCREENING; EMERGENCY HEALTH SERVICE; FEMALE; FINLAND; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCREENING; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGE FACTORS; AGED; AGING; ALPHAPAPILLOMAVIRUS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; FINLAND; HUMANS; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIAGE; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 71549139773     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp367     Document Type: Article

References (28)

1. International Agency for Research on Cancer. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC Press 2007.
2. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 (suppl 10): K29-K41
3. Arbyn M, Anttila A, Jordan J, et al., eds. European Guidelines for Quality Assurance in Cervical Cancer Screening. Brussels, Belgium: Offi ce for offi cial publications of the European Communities 2008.
4. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004; 110 (1): 94-101.
5. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomized controlled trial. Lancet Oncol. 2006; 7 (7): 547-555. (Pubitemid 43923665)
6. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98 (11): 765-774. (Pubitemid 43983300)
7. Elfgren K, Rylander E, Rådberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005; 193 (3, pt 1): 650-657.
8. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer. 2006; 95 (1): 56-61.
9. Kotaniemi-Talonen L, Anttila A, Malila N, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer. 2008; 44 (4): 565-571.
10. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papilloma-virus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357 (16): 1579-1588.
11. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357 (16): 1589-1597.
12. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet. 2007; 370 (9601): 1764-1772.
13. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008; 377 (Oct): a1754.
14. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer. 2005; 92 (9): 1800-1802.
15. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95 (1): 46-52.
16. Nieminen P, Hakama M, Viikki M, Tarkkanen J, Anttila A. Prospective and randomized public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the fi rst year. Int J Cancer. 2003; 103 (3): 422-426.
17. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomized setting. Br J Cancer. 2005; 95 (8): 862-867.
18. Anttila A, Nieminen P. Cervical cancer screening program in Finland with an example on implementing alternative screening methods. Coll Antropol. 2007; 31 (suppl 2): 17-22.
19. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomized evaluation trial. BMC Public Health. 2006; 16 (6): 252.
20. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157 (10): 940-943.
21. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papil-lomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specifi city, and frequency of referral. JAMA. 2002; 288 (14): 1749-1757.
22. Agorastos T, Dinas K, Lloveras B, et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecol Oncol. 2005; 96 (3): 714-720.
23. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008; 100 (7): 492-501.
24. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined signifi cance. Am J Obstet Gynecol. 2003; 188 (6): 1383-1392.
25. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006; 367 (9509): 489-498.
26. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2007; 109 (2, pt 1): 309-313.
27. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119 (5): 1095-1101.
28. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 84 (12): 1616-1623